Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Semaglutide users experienced an average Weight loss of 9.1% (approximately 8.7 kg), while tirzepatide users lost 21.4% of their body weight (approximately 49.4 lbs)
If you experience any severe or persistent symptoms, such as difficulty breathing, swelling, or signs of an allergic reaction, seek medical attention immediately
1 Authorization in Canada under the NOC/c guidance was granted based on the acceptable safety profile, high quality and promising efficacy of Wegovy (semaglutide injection) observed in Part 1 of the phase 3 ESSENCE trial
Gastrointestinal effects are the most commonly reported for each, especially during dose escalation
US$ 26.03
US$ 21.72
US$ 23.43
US$ 25.43
